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Abstract
Purpose: This manuscript discusses the importance of establishing risk indicator monitoring guidelines for state Early 
Hearing Detection and Intervention programs.
Method: Idaho Sound Beginnings (ISB) implemented a guideline which divided risk indicators associated with delayed-
onset hearing loss into two classes (Class A and Class B). From 2012–2013, the incidence of delayed-onset hearing loss 
in the presence of Class A and Class B risk indicators were evaluated. For Class B risk indicators, ototoxic medication 
exposure and family history were analyzed. 
Results: Of the 10,634 infants born, 1,175 were found to have passed the newborn hearing screening and have at least 
one risk indicator. Of the infants evaluated with Class A risk indicators, 21 children had an educationally significant hearing 
loss. Of the 345 children who received ototoxic medications, 55 children were diagnosed with educationally significant 
hearing loss.  An educationally significant hearing loss was found in 10 children who returned for diagnostic evaluation 
who had family history of childhood hearing loss. 
Conclusion: ISB’s risk monitoring classification system has enhanced Idaho’s EHDI program by early identification of 
children who are at higher risk for delayed-onset hearing loss. Early identification has ultimately led to early intervention.
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The Joint Committee on Infant Hearing (JCIH) was 
established in 1969 to investigate the need for mass 
screening programs in an effort to identify children 
with hearing loss earlier in life. In 1973, the JCIH 
recommended using criteria to identify newborns at risk 
for hearing loss. Over the next five position statements, 
JCIH modified the criteria based on research and 
clinical findings. The suggested audiological monitoring 
schedule ranged from strict (e.g., monitor hearing every 
six months until the age of 3; JCIH, 2000) to lax (e.g., at 
least one diagnostic evaluation by 24–30 months of age; 
JCIH, 2007). The variability in the monitoring schedules 
has the potential to create confusion for physicians 
and audiologists. The JCIH 2007 Position Statement 
recommended earlier and more frequent monitoring for 
some risk indicators with higher prevalence of delayed-
onset hearing loss. For others, the JCIH 2007 Position 
Statement indicates one monitoring appointment by 
at least 24–30 months of age may be sufficient. To 
efficiently implement these recommendations, the 
use of a systematic approach may be appropriate. 
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In 2011, Idaho Sound Beginnings (ISB) developed a 
classification system of the 2007 JCIH risk indicators to 
provide guidance to those involved with newborn hearing 
screening programs regarding when to refer infants to 
pediatric audiologists for risk monitoring of delayed-onset 
hearing loss. This article will discuss the development 
of this classification system for the JCIH (2007) risk 
indicators and initial findings after implementation within 
two hospitals.
Introduction
Monitoring JCIH 2007 Risk Indicators
JCIH published the most recent position statement in 2007. 
As shown in Table 1 the statement listed risk indicators 
associated with permanent congenital, delayed-onset, or 
progressive hearing loss in childhood. The neonatal risk 
indicators were redefined to specifically include neonatal 
intensive care of more than five days or any of the following 
regardless of length of stay: Extracorporeal membrane 
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oxygenation (ECMO), assisted ventilation, exposure to 
ototoxic medications (gentamycin and tobramycin) or 
loop diuretics (furosemide/Lasix), and hyperbilirubinemia 
that requires exchange transfusion (JCIH, 2007). The 
monitoring schedule was also redefined to include at 
least one diagnostic audiology assessment by 24 to 
30 months of age. Additionally, the time and number of 
hearing evaluations for children with risk indicators should 
be customized and individualized (JCIH, 2007), giving the 
clinical judgement back to the audiologists and the medical 
home. Earlier and more frequent assessments may be 
indicated for some risk indicators with higher prevalence 
of delayed-onset hearing loss. For others, one diagnostic 
appointment may be sufficient. 
Table 2
Individual Risk Indicators Associated with Hearing Loss Occurring Most and Least 
Frequently (Hall, 2007)
Most frequent
Craniofacial anomalies (> 50%)
Family history of childhood hearing loss (> 15%)
Severe asphyxia (> 15%)
Congenital infections (> 15%)
Mechanical ventilation (> 10%)
Bacterial meningitis (> 10%)






Note. ECMO = extracorporeal membrane oxygenation.
Table 1
JCIH 2007 Position Statement Risk Indicators
Caregiver concern regarding hearing, speech, language, or development delay
Family history of permanent childhood hearing loss 
Neonatal intensive care of more than 5 days or any of the following regardless of length of stay: 
extracorporeal membrane oxygenation (ECMO), assisted ventilation, exposure to ototoxic medications
(gentimycin and tobramycin) or loop diuretics (furosemide/Lasix), and hyperbilirubinemia that requires
exchange transfusion
In utero infections, such as cytomegalovirus (CMV), herpes, rubella, syphilis, and toxoplasmosis
Craniofacial anomalies, including those that involve the pinna, ear canal, ear tags, ear pits, and 
temporal bone anomalies
Physical findings, such as white forelock, that are associated with a syndrome known to include a
sensorineural or permanent conductive hearing loss
Syndromes associated with hearing loss or progressive or delayed-onset hearing loss, such as 
neurofibromatosis, osteopetrosis, and Usher syndrome; other frequently identified syndromes including
Waardenburg, Alport, Pendred, and Jervel and Lange-Nielson
Neurodegenerative disorders, such as Hunter syndrome, or sensory motor neuropathies, such as Friedreich 
ataxia and Charcot-Marie-Tooth syndrome
Culture-positive postnatal infections associated with sensorineural hearing loss, including confirmed bacterial
and viral (especially herpes viruses and varicella) meningitis
Head trauma, especially basal skull/temporal bone fracture that requires hospitalization
Chemotherapy
The following risk indicators were listed in the JCIH 2007 
Position Statement as being of greater concern for delayed-
onset hearing loss: caregiver concern, family history of 
hearing loss, ECMO, cytomegalovirus (CMV), syndromes 
associated with hearing loss, neurodegenerative 
disorders, culture-positive postnatal infections associated 
with sensorineural hearing loss, head trauma, and 
chemotherapy. When considering only those infants in 
the at-risk population who were diagnosed with hearing 
loss, Hall (2007) reviewed the frequency of occurrence 
of individual risk indicators associated with hearing 
loss and identified six risk indicators that occurred most 
frequently (as shown in Table 2). Hall (2007) highlighted 
the importance of audiological professionals who work with 
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the infant population being intimately familiar with all risk 
indicators for hearing loss whether peripheral, auditory 
dysfunction, or delayed onset.
In 2012, Beswick, Driscoll, and Kei systematically identified 
753 publications from 1973 to March 2011 and reviewed 40 
of those publications to draw evidence-based conclusions 
on risk indicators and risk monitoring programs that detect 
postnatal hearing loss. They found the most common risk 
indicators reported were “gestational-age, low-birth weight, 
toxoplasmosis, other infections, rubella, CMV, herpes 
simplex virus infections, craniofacial anomalies, respirator 
support, and the administration of aminoglycosides” (p. 
745). Based on two of the publications reviewed, 3 to 3.5% 
of infants were referred for follow-up testing due to the 
presence of risk indicators defined by each study. Authors 
found a strong relationship between postnatal hearing 
loss and CMV, congenital diaphragmatic hernia, ECMO, 
and persistent pulmonary hypertension. Conversely, a 
weak link was found between postnatal hearing loss and 
toxoplasmosis, pre-auricular skin tags and ear pits, and low 
birth weight.
A retrospective study by Beswick, Driscoll, Kei, Khan, 
and Glennon (2013) evaluated audiological findings for 
2,107 children who were identified with one or more risk 
indicators for hearing loss. Of children who initially passed 
the newborn hearing screening but had risk indicator(s), 
2.7% were diagnosed with hearing loss. A statistical 
analysis identified family history and craniofacial anomalies 
to be high predictors for postnatal hearing loss, whereas, 
low birth weight was a low predictor.
Wood, Davis, and Sutton (2013) retrospectively examined 
the effectiveness of targeted surveillance to identify 
moderate-profound permanent childhood hearing 
impairment in babies who passed the newborn hearing 
screening in the presence of risk indicators for delayed-
onset hearing loss in England. England newborn hearing 
screening program data (n = 2,307,880 children) was 
reviewed from 2006 to 2009. Based on follow-up evaluation 
of more than 38,000 infants who passed newborn hearing 
screening with risk factor for delayed-onset hearing loss, 
five factors were identified as most often associated with 
permanent childhood hearing impairment: syndrome 
(other than Down’s) associated with a hearing loss, 
neonatal intensive care unit (NICU) with refer in both 
ears at otoacoustic emissions (OAE) and pass in both 
ears at automatic auditory brainstem response (AABR), 
craniofacial anomaly, Down’s syndrome, and congenital 
infection. Monitoring only these five criteria was estimated 
to reduce the percentage of the birth population that 
require targeted surveillance from 3% to 0.25% (Wood 
et al., 2013). It was also noted that neonatal bacterial 
meningitis and aminoglycoside antibiotics were not 
considered in this review. Bacterial meningitis occurring 
before the hearing screen is considered a contraindication 
to screening and patients are referred directly for a full 
audiological assessment. The protocol of England’s 
newborn hearing screening program states that babies who 
receive aminoglycoside and have blood levels exceeding 
the therapeutic range should be referred for audiological 
assessment by the prescribing pediatrician. Otherwise, 
screening programs in England no longer record 
aminoglycoside as a risk factor. 
Kraft, Malhotra, Boerst, and Thorne (2014) evaluated the 
economic impact of monitoring children with risk indicator 
for delayed-onset hearing loss. University of Michigan 
newborn hearing screening program data was reviewed 
from 2001 to 2007. Ninety children were diagnosed with 
hearing loss, including 16 children with delayed-onset 
hearing loss. They concluded that a “NICU stay of greater 
than 5 days and exposure to loop diuretics were not 
associated with an increased risk of either congenital or 
delayed-onset hearing loss” (p. 1842). Monitoring children 
with these risk indicators, NICU length of stay greater than 
five days, or exposure to potentially ototoxic medications, 
in the absence of other risk indicators was reported to 
have “increased the monitoring burden” nearly five times 
which “contributes to the high cost of screening per case 
identified” (p. 1842).
Vos, Senterre, Lagasse, SurdiScreen Group, and Levêque 
(2015) retrospectively evaluated the clinical management 
and follow-up of newborns with neonatal risk indicators of 
hearing loss for the newborn screening program in Belgium 
to systematically update the monitor recommendations. 
The group completed a literature review of 15 years of 
publications and graded the quality of evidence found in 
regard to the risk indicators for delayed-onset hearing loss 
as defined by the 2000 JCIH Position Statement and the 
clinical experience of professionals from the Fédération 
Wallonie-Bruselles. The study found congenital infections 
(i.e., cytomegalovirus, toxoplasmosis, and syphilis), a 
family history of hearing loss, consanguinity, malformation 
syndromes, and fetal alcohol syndrome to have a high level 
of evidence quality as neonatal risk indicators for hearing 
loss. Additionally, hyperbilirubinemia had a moderate level 
of evidence quality while very low birth weight, low Apgar 
score, ototoxic drugs, and hospitalization in the NICU 
had a very low or low level of evidence quality. Vos et al. 
recommended monitoring all risk indicators for hearing 
loss, even those with weak evidence, in order to avoid 
“unidentified neonatal hearing loss” (p. 6). The authors also 
recommended completing the initial hearing evaluation 
for those newborns with any of these risk indicators prior 
to discharge from the hospital using at least an auditory 
brainstem response (ABR) to assess the entire auditory 
brainstem pathway.
Review of current literature on risk indicators for delayed-
onset hearing loss revealed variability in which risk 
indicators should be monitored, which risk indicators 
have increased risk for delayed-onset hearing loss, and 
variability on how and when to monitor individual risk 
indicators. The JCIH 2007 Position Statement provided 
guidance for Early Hearing Detection and Intervention 
(EDHI) programs on which risk indicators to monitor and 
which risk indicators have increased risk for delayed-
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onset hearing loss. Unfortunately, the JCIH 2007 Position 
Statement did not provide concrete guidance on when 
to begin monitoring (i.e., what age), how often to monitor 
(i.e., months vs. years), and how long to continue 
monitoring (i.e., until what age). The purpose of the ISB risk 
monitoring classification system was to provide guidance to 
stakeholders in Idaho newborn hearing screening programs 
regarding when to refer infants for risk monitoring of 
delayed-onset hearing loss.
Idaho Monitoring Risk Indicators
In October 2011, with guidance from the ISB pediatric 
audiology consultant, hospitals with NICU programs in 
Idaho began collecting data on early and more frequently 
monitored risk indicators. Indicators with higher incidence 
and earlier onset of hearing loss were classified as Class 
A and all other risk indicators were classified as Class B. 
This classification system was based on the JCIH 2007 
Position Statement and evidence-based research on 
craniofacial anomalies. The JCIH 2007 Position Statement 
and additional studies (Vos et al., 2015; Beswick et al., 
2013; Wood et al., 2013) identified early and more frequent 
assessment may be indicated for children with CMV 
infection; syndromes associated with progressive hearing 
loss, neurodegenerative disorders, trauma, or culture-
positive postnatal infections associated with sensorineural 
hearing loss; and for children who have received ECMO or 
chemotherapy. Those risk indicators were designated Class 
A. Cleft palate was also included in the Class A category 
based on evidence-based research on craniofacial 
anomalies from multiple publications (Beswick et al., 2013; 
Helias, Chobaut, Mourot, & Lafon, 1988; Paradise, 1975; 
Potsic, Cohen, Randall, & Winchester, 1979; Viswanathan, 
Vidler, & Richard, 2008; Yules, 1970). All other risk 
indicators identified by the JCIH 2007 Position Statement 
were categorized in Class B including family history of 
childhood hearing loss, other in-utero infections (not CMV), 
NICU stay of greater than five days, any amount of ototoxic 
exposure, any amount of mechanical ventilation, and other 
craniofacial anomalies excluding cleft palate (Kraft et al., 
2014; Wood et al., 2013). See Figure 1 for Class A and 
Class B lists.
The terminology of Class A and B were defined based 
on a collaborative effort between a neonatologist and 
a pediatric audiology consultant. The Class terms are 
commonly used within the NICU environment and readily 
identified by the medical community. Infants with Class 
A risk indicators were recommended for evaluations by a 
pediatric audiologist by 3 months of age. At a minimum, 
the evaluation should include diagnostic ABR. Infants with 
Class B risk indicators were recommended for a behavioral 
hearing evaluation by a pediatric audiologist by 1 year of 
age. Guidelines provided to Idaho pediatric audiologists 
indicate, at a minimum, the evaluation should include 
ear specific measurements at multiple frequencies as 
recommended by the JCIH 2007 Position Statement when 
evaluating a child 6 to 36 months of age
.
The purpose of the risk indicator classification system is 
to allow for early identification of children with delayed-
onset hearing loss. In Idaho, when a child is identified 
with hearing loss the diagnosing audiologist completes 
the ISB audiology results form (Figure 2) and submits it 
to ISB. This form also serves as a release of information 
to early intervention programs within the state of Idaho 
including Infant Toddler Program, Idaho Education 
Services for the Deaf and the Blind, and Idaho Hands and 
Voices. Therefore, the risk indicator classification system, 
subsequent early diagnosis of hearing loss, and the ISB 
reporting process should lead to timely enrollment in 
early intervention.
Method
ISB, Idaho’s EHDI program, has been collecting data 
on risk indicators since the implementation of the Idaho 
EHDI program using Hi*Track data collection system. 
Implementation of the Class A and Class B classification 
system did not alter how data within Hi*Track was collected 
or maintained. Hi*Track allows for retrospective analysis of 
risk indicators based on the two-class classification system. 
Idaho birthing hospitals report information regarding risk 
indicators with results of each newborn hearing screening. 
A positive family history of childhood hearing loss is self-
reported by families. The presence of other risk indicators 
is identified from a review of the infant’s medical chart. 
Diagnostic audiological findings are reported to ISB by 
Idaho audiologists using the ISB audiology results form 
(Figure 2).
Data of infants born from January 2012 through December 
2013 for two of the larger hospitals with NICU programs 
in the state of Idaho were reviewed. Data on infants 
who passed the newborn hearing screening and were 
identified as having one or more risk indicators were 
included in the review. Infants who referred on the newborn 
hearing screening and had present risk indicators were 
excluded from the study. Data was collected for analysis 
in November 2015, all diagnostic audiological follow-up 
information reported to ISB at that time was available 
for review.
Results
According to ISB Hi*Track, 10,634 infants were born at the 
two selected hospitals in Idaho during this time frame. Of 
the 10,634 infants reviewed, 1,175 (11.04%) infants were 
found to have passed the newborn hearing screening and 
have at least one risk indicator in either Class A or Class 
B.  From these infants, 175 (1.6%) infants were found to 
have passed the newborn hearing screening and have at 
least one Class A risk indicator. Infants within the first group 
of Class A risk indicators could also be represented in the 
second group of either Class A or Class B risk indicators. 
Infants with Class A risk indicators frequently have at least 
one risk indicator from the Class B list which accounts 
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Guidelines for   
Risk Monitoring for Delayed Onset Hearing Loss 
 
450 W. State St. Floor-5, Boise, ID 83702      www.IdahoSoundBeginnings@dhw.idaho.gov      208-334-0829 
NOTE:   If baby REFERS on the newborn hearing screening after two attempts – Recommendation      
for Diagnostic ABR evaluation to be completed by 3 months of age (JCIH 2007) 
* Any parental/caregiver hearing concerns warrants a referral to a pediatric audiologist.   
** Infants readmitted to the hospital within the first 30 days of life should be re-screened if any 
risk indicators are present.   
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Fligor BJ, Neault MW, Mullen CH, Feldman HA, Jones DT. Factors associated with sensorineural hearing loss among survivors of extracorporeal membrane 
oxygenation therapy. Pediatrics 2005; 115(6):1519-1528. 
Joint Committee on Infant Hearing. Year 2007 Position Statement: Principles and Guidelines for Early Hearing Detection and Intervention Programs. 
Pediatrics. 2007; 120(4):898–921. doi: 10.1542/peds.2007-2333. 
Van Riper, Lori A.; Kileny, Paul R. ABR Hearing Screening for High-Risk Infants.  American Journal of Otology. 20(4):516-521, July 1999.  
 
Class A: Risk indicators 
*In-utero infections (congenital CMV) 
*Culture Positive postnatal infection 
(Bacterial and viral meningitis)  
*Syndromes associated with 
progressive or delayed onset hearing 
loss (Neurofibromatosis, 
Osteopetrosis, Usher Syndrome, 
Townes-Brock) 
*Syndromes associated with hearing 
loss (Down syndrome and Sticklers) 
*Cleft Lip/Palate 
*ECMO assisted ventilation 
*Head Trauma involving basal 
skull/temporal fracture that requires 
hospitalization 
*Chemotherapy treatments 
*Neurodegenerative disorders or 
sensory motor neuropathies 
If baby passes the newborn hearing 
screening & has one or more CLASS A 
risk indicator =  
Recommendation for diagnostic ABR 
evaluation with pediatric audiologists 
by 3 months of age. 
Class B: Risk indicators 
*Family history of childhood hearing 
loss 
*In-Utero Infection (Herpes, Rubella, 
Syphilis, Toxoplasmosis) 
*NICU stay of greater than 5 days 
*Any amount of ototoxic exposure 
(aminoglycosides) 
*Any amount of mechanical 
ventilation 
*Craniofacial anomalies involving 
pinna, ear canal, ear pits and 
temporal bone anomalies 
If baby passes the newborn hearing 
screening & has one or more CLASS B 
risk indicators =  
Recommendation for diagnostic 
pediatric hearing evaluation by 1 year 
of age. 
Figure 1. Idaho Sound Beginnings guidelines for risk monitoring for delayed-onset hearing loss
60Figure 2. Idaho Sound Beginnings audiology results form. 
61
for the crossover of the two groups. The number of risk 
indicators reported from this population totaled 2,614 
(Figure 3).
Of the 175 infants with Class A risk indicators, 87 returned 
for comprehensive diagnostic audiology evaluations. 
Of those, 25% (21 of 87 infants) were found to have 
an educationally significant hearing loss. Educationally 
significant hearing loss is defined as any type of hearing 
loss (chronic conductive, sensorineural, or mixed hearing 
loss), unilateral or bilateral, at 25 dB or greater (worse) 
at one or more frequencies. Of the 25% that were 
diagnosed with hearing loss, five (5.7%) were found to 
have sensorineural or mixed hearing loss. The Class A 
risk indicators present in these five children included two 
children with cleft palate, one child with Townes Brock 
syndrome, one child with Acrofacial Dysostosis, and one 
child with congenital CMV. The most common Class A 
indicators present in this population were syndromes (e.g., 
Down’s Syndrome) and cleft palate.
Of the 1,175 infants who passed the newborn hearing 
screening and were identified as having at least one risk 
indicator within Class A and Class B categories, 743 infants 
received ototoxic medication, most commonly gentamicin. 
Of those infants who received ototoxic medication, 345 
(46.4%) returned for follow-up diagnostic audiological 
evaluation and 55 (15.9%) were diagnosed with 
educationally significant hearing loss, five (1.4%) of which 
were sensorineural or mixed hearing loss and 50 (14.4%) 
were chronic conductive hearing loss. Of the five infants 
diagnosed with sensorineural or mixed hearing loss, three 
presented with Class A risk indicator along with the Class 
B ototoxic medication exposure. The remaining two infants 
presented with additional Class B indicators along with 
ototoxic medication exposure, specifically extended NICU 
stay and prematurity. 
Over half of the infants (n = 398; 53.6%) who were 
identified as having the Class B risk indicator of ototoxic 
medication exposure were lost to follow-up. If the trend 
found for this population can be generalized to the 
children who did not receive follow-up evaluations, then 
approximately 63 infants have educationally significant 
hearing losses and did not benefit from early diagnosis and 
intervention. 
Of the 1,175 infants who passed the newborn hearing 
screening and were identified as having at least one risk 
indicator, 175 infants were identified as having present 
family history of permanent childhood hearing loss which 
is a Class B risk indicator. Of the 175 infants, 65 (37.1%) 
returned for diagnostic audiology evaluation for a lost 
to follow-up rate of 62.8%. This was the highest lost to 
follow-up rate of all the risk indicators present within 
this population. An educationally significant hearing loss 
was found in 10 (16%) of those infants that returned for 
diagnostic evaluation, three of which were sensorineural 
or mixed hearing loss and seven were chronic conductive 
hearing loss. Additional risk indicators were present in 
only one of the three infants diagnosed with sensorineural 
or mixed hearing loss, indicating that family history of 
permanent childhood hearing loss was the only indicator to 
assist with early identification of hearing loss in these two 
infants. 
Age of diagnosis was reviewed in all children identified with 
educationally significant hearing loss in the population. 
Children with educationally significant hearing loss were 
identified prior to 24 months of age. Children identified 
with Class A risk indicators returned for initial audiological 
evaluation at an average of 4 months of age (range = 2 to 
9 months). Children identified with Class B risk indicators 
returned for initial audiological evaluation at an average 
Figure 3. Reported risk indicators from Idaho Sound Beginnings Hi*Track database 





























































































of 11.3 months of age (range = 9 to 13 months). The nine 
children found to have sensorineural or mixed hearing 
loss were diagnosed at an average of 12.6 months of age 
(range = 4 to 24 months). 
Discussion
ISB’s goal of using the risk monitoring classification system 
was to identify infants with the higher risk for delayed-onset 
hearing loss (i.e., Class A) and refer them to audiology 
for earlier and more frequent monitoring per JCIH (2007) 
recommendation. The infants with Class B indicators who 
have lower incidence of delayed-onset hearing loss would 
warrant less frequent monitoring. In this study, children with 
a Class A risk indicator and delayed-onset hearing loss 
were seen for initial evaluation by 10 months old (range = 
2 to 9 months) and diagnosed by 25 months of age (range 
= 4 to 24 months). One infant who was diagnosed at age 
24 months was monitored for delay-onset hearing loss 
beginning at 3 months of age. Due to the Class A risk factor 
of cleft palate, the child was monitored every 6 months on 
the recommendation of the managing audiologist. At 24 
months of age a sensorineural hearing loss was diagnosed 
in this child. Because of the JCIH (2007) position statement 
recommendation to monitor earlier and more frequent for 
some risk indicators, this hearing loss was identified. The 
Class A and Class B classification system was designed 
to refer children for audiological evaluation at appropriate 
times based on the presence of risk indicators for delayed-
onset hearing loss. Once a child is initially referred for risk 
indicator monitoring, it is at the discretion of the managing 
audiologist to set the future monitoring schedule. 
The findings of the Class B ototoxic medication exposure 
in the study population align with Cone-Wesson et al. 
(2000) and Van Riper and Kileny (1999; 2002), identifying 
a high occurrence of the risk factor with a low prevalence 
of associated hearing loss. Although a low incidence, early 
identification is critical for those infants and their families 
impacted by hearing loss related to ototoxic medication 
exposure. Based on previous research, including Prezant 
et al. (1993), damage from ototoxicity typically occurs 
within the cochlea. This suggests an evaluation of cochlear 
outer hair cell function is the most appropriate tool to 
triage this population to determine necessity of further 
audiological evaluation. OAE testing has been reported 
as a non-invasive, cost-effective physiologic measure of 
cochlear outer hair cell function (JCIH, 2007; Kezirian, 
White, Yueh, & Sullivan, 2001). Therefore, an OAE test 
using an ototoxic protocol alone could suffice as a triage 
protocol for this risk indicator to determine if further 
diagnostic evaluation is necessary. Implementing OAE 
triage evaluation to optimize the audiology diagnostic test 
protocols should be considered to decrease economic 
impact and improve program efficiency. 
The Class B risk indicator of family history of permanent 
childhood hearing loss was the third most reported risk 
indicator in this population. It is also the most frequently 
reported risk indicator from the well-baby population (Hall, 
2007; ISB, 2007–2013). Beswick et al. (2013) reported 
that children with a family history of permanent childhood 
hearing loss were nearly two times more likely to develop 
a postnatal hearing loss than those without such family 
history. Unfortunately, given the lost to follow-up rate of 
63% within the current study population, we are potentially 
missing early diagnosis of more than 17 children with 
educationally significant hearing loss during this time frame. 
Potential factors for lost to follow-up which have been 
cited include maternal race/ethnicity, maternal smoking 
during pregnancy, public insurance coverage, and area of 
residence within the state (Liu, Farrell, MacNeil, Stone, & 
Barfield, 2008).
A question to consider is if family history is reported by the 
parents, then why is it the highest lost to follow-up rate? To 
address this question, risk indicator monitoring programs 
may want to consider improvement in the following two 
areas: 1) explanation of criteria for family history of hearing 
loss, and 2) scripts for screeners to inquire about family 
history of hearing loss. If programs rely on families to 
interpret family history of hearing loss then reports will more 
than likely include middle ear dysfunction, presbycusis, 
and noise induced hearing loss or other acquired hearing 
loss not due to congenital or genetic factors. To improve 
the family reported presence of family history of childhood 
hearing loss and subsequently reduce the lost to follow-
up rate for this population, scripts for screeners should 
be provided which detail the criteria for family history of 
hearing loss. Additionally, when the risk factor is present, 
the family should be provided with an explanation of the risk 
factor and why it is important to receive follow-up services. 
If the high rate of diagnosing educationally significant 
hearing loss in the presence of family history risk indicator 
is accurate, consideration should be given to placing the 
risk indicator of family history in the Class A category.  
During this data review, families were provided with 
information regarding the risk indicator present and the 
need for future follow-up based on the risk indicator 
classification system. Additionally, audiology clinics who 
received the ISB referral forms attempted to contact the 
families to schedule appropriate follow-up diagnostic 
appointments based on the risk indicator classification 
system. Attempts to contact infants listed in the Class 
A classification were made by 3 months of age, 
while attempts to contact infants listed in the Class B 
classification were made by approximately 9 months of 
age. Recently, additional steps have been implemented by 
ISB to reduce the lost to follow-up rate in Idaho. A letter is 
mailed to the child’s primary care physician immediately 
following identification of an infant who passes their 
newborn hearing screening with present risk indicators. A 
letter is also mailed to the child’s parents at approximately 
6 months of age reminding the parents to schedule an 
appointment with a pediatric audiologist. Further research 
is necessary to determine the impact, if any, on the lost to 
follow-up rate with the implementation of reminder letters 
from ISB to physicians and parents. 
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The JCIH (2007) recommendation of completing at least 
one diagnostic evaluation by 24 to 30 months of age is 
fairly broad compared to the JCIH 2000 guidelines which 
recommended monitoring all risk indicators every 6 months 
until 3 years of age. During 2012–2013, the ISB program 
used the Class A and Class B monitoring schedules and 
by doing so children with sensorineural hearing loss were 
identified prior to 24 months of age. Using the two-class 
system schedule to provide ongoing monitoring for the 
Class A risk indicators and one-time monitoring for the 
Class B risk indicators reduces burden to families and all 
stakeholders while maintaining an appropriate level for 
those indicators that pose a higher level of risk. On average 
children were diagnosed with sensorineural hearing loss 
by 12 months of age. Having risk monitoring guidelines for 
state EHDI programs provides structure to the JCIH (2007) 
recommendations and appears to decrease the diagnosis 
age for children with risk indicators for delayed-onset 
hearing loss. As previously mentioned, earlier diagnosis of 
delayed-onset hearing loss should lead to timely enrollment 
into early intervention. Further research investigating the 
impact of the risk indicator classification system on timely 
enrollment into early intervention is indicated.
Summary
Use of the risk monitoring classification system has 
enhanced Idaho’s EHDI program by providing access 
to early identification of children who are at higher risk 
for delayed-onset hearing loss. Subsequently, the early 
identification of children with delayed-onset hearing loss 
should lead to timely early intervention. Unfortunately, the 
high lost to follow-up rate (e.g., over 60% in Idaho) for 
infants with risk indicators indicates a need for ongoing 
program improvement. 
Monitoring for the risk indicator of ototoxic medication 
exposure continues to be warranted as indicated by 
previous and current research. Further research on the 
potential risk of hearing loss from ototoxic medication 
exposure is required. With regards to infants with only 
ototoxic medication exposure, effort should be focused on 
optimizing the audiology diagnostic test protocols while 
considering program efficiency and economic impact.
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